ICUIICUIHealthcare · Medical Instruments & Supplies

ICUI Stock Forecast: ICU Medical, Inc. Price Predictions for 2026-2027

Last close, 11 Nov 2026
$178
−2.13% on the day

The 8 Wall Street analysts covering ICU Medical, Inc. hold a median 12-month price target of $195 — +9.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 11 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.6B
Ticker Nerd rank
95/ 100
Median analyst target
$195
Analysts covering
8
Revenue$551.7M+0.5% y/y
Operating income$60.4M
Net income$19.1M
Free cash flow$60.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.3%
1M
+11.2%
YTD
+24.9%
1Y
+24.5%
From 52W high
−4.8%
From 52W low
+54.4%
$115
$187
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ICUI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ICU Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Nov 2026
95/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
94
Volatility
88
Issuance
82
Accruals
81
Momentum
80
Revisions
79
Quality
64
Growth
57
Size
25

Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (57): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ICUI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICUI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180$200$220Jan 26Apr 26Jul 26Oct 26ICUIHigh $210Median $195Low $178

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $178Median $195High $210

The green dot is the last close — the median target sits +9.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Nov 2026KeybancMaintainsOverweight$187 → $189
6 Nov 2026Piper SandlerMaintainsOverweight$195 → $200
7 Aug 2026BTIGMaintainsBuy—
7 Aug 2026BTIGMaintainsBuy$170 → $200
7 Aug 2026NeedhamMaintainsBuy—
7 Aug 2026NeedhamMaintainsBuy$165 → $187
7 Aug 2026Piper SandlerMaintainsOverweight—
7 Aug 2026Piper SandlerMaintainsOverweight$163 → $195
21 July 2026KeybancMaintainsOverweight$164 → $182
21 July 2026KeybancMaintainsOverweight—
15 June 2026BTIGInitiatesBuy—
15 June 2026BTIGInitiatesBuy$170
27 May 2026NeedhamUpgradeBuy—
27 Apr 2026KeybancMaintainsOverweight—
17 Apr 2026Piper SandlerMaintainsOverweight—
20 Feb 2026KeybancMaintainsOverweight—
20 Feb 2026Piper SandlerMaintainsOverweight—
7 Nov 2025KeybancMaintainsOverweight—
7 Nov 2025Piper SandlerMaintainsOverweight—
21 Oct 2025KeybancMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ICUI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time.

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ICUI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Nov 2026, ICU Medical, Inc. returned +24.5% against +12.4% for the S&P 500, dividends included.

ICUI vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Jan 26Apr 26Jul 26Oct 26ICUIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ICUI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+3.0%
Analysts raising
8
Analysts cutting
0
Fundamentals

ICU Medical, Inc. (ICUI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
76.2×

Cheaper than 9% of US stocks

Price / sales
2.1×

Cheaper than 49% of US stocks

Price / book
2.1×

Cheaper than 41% of US stocks

EV / EBITDA
15.7×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
4.4%

Higher than 39% of US stocks

Earnings growth (YoY)
0.5%

Higher than 37% of US stocks

Gross margin
42.6%

Higher than 53% of US stocks

Operating margin
8.6%

Higher than 62% of US stocks

Net margin
2.8%

Higher than 54% of US stocks

Returns & dividend
Return on equity
2.8%

Higher than 48% of US stocks

Return on assets
2.3%

Higher than 60% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ICU Medical, Inc. (ICUI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ICU Medical, Inc. has a market value of $4.6B and an enterprise value of $5.5B.

  • Revenue in the twelve months to 30 June 2026: $2.2B. The latest quarter grew 4.4% year on year.

  • Net income over the same four quarters: $30.1M, a 1.4% net margin.

  • Diluted earnings per share, trailing twelve months: $1.18.

  • Free cash flow in the twelve months to 30 June 2026: $144.8M.

  • Shares outstanding: 25.0M.

  • Trailing P/E: 76.2×; forward P/E: 18.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ICU Medical, Inc. employs 13,000 people — $166K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Nov 2026

Data provided by Twelve Data

Peers

ICUI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
ICUIICU Medical, Inc.$4.6B95
PLSEPulse Biosciences, Inc.$4.1B56
NVSTEnvista Holdings Corp.$4.1B95
STVNStevanato Group SpA$3.8B60
MMEDMiniMed Group, Inc.$5.1B1
WRBYWarby Parker, Inc.$3.7B33
MMSIMerit Medical Systems, Inc.$5.3B85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ICU Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ICUI news & analysis

ICU Medical Q3 Earnings Call Highlights

MarketBeat · 6 Nov 2026positive

ICU Medical reported third-quarter revenue of $556 million and said it expects full-year adjusted earnings to finish toward the high end of its existing guidance. Growth in infusion products and improved margins offset a decline in Vital Care.

Why it matters — ICUI watchers may note the reported revenue and the company’s outlook for adjusted earnings alongside differing performance across its product areas.

ICU Medical (ICUI) Beats Q3 Earnings and Revenue Estimates

Zacks Investment Research · 6 Nov 2026positive

ICU Medical reported quarterly earnings of $2.44 per share, above the Zacks Consensus Estimate of $2.14. Earnings were $2.03 per share in the year-ago quarter.

Why it matters — ICUI watchers may note that quarterly earnings exceeded the consensus estimate and were higher than a year earlier.

ICU Medical (ICUI) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 6 Nov 2026neutral

Zacks Investment Research says ICU Medical’s headline Q3 earnings numbers for the quarter ended September 2026 provide insight into its performance. The item suggests comparing key metrics with Wall Street estimates and year-ago actuals.

Why it matters — Those comparisons offer ICUI watchers additional context for assessing the quarter’s results.

ICU Medical, Inc. (ICUI) Q3 2026 Earnings Call Transcript

Seeking Alpha · 5 Nov 2026neutral

The listed item is a Seeking Alpha transcript of ICU Medical, Inc.’s Q3 2026 earnings call; no additional call details are provided in the excerpt.

Why it matters — ICUI watchers can note that the Q3 2026 earnings call transcript is available, but the excerpt contains no specific company updates or results.

FAQ

Frequently asked questions about ICUI stock

What is the ICUI stock price forecast for 2026-2027?

The 8 Wall Street analysts covering ICU Medical, Inc. have a median 12-month price target of $195, with estimates ranging from $178 to $210. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ICUI stock a buy right now?

Of the 8 analysts covering ICU Medical, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ICU Medical, Inc. 95 out of 100 across roughly 4,600 US stocks as at 11 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ICUI?

As at 11 Nov 2026, ICU Medical, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).

Will ICUI stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +9.4% from the last close, and Ticker Nerd's factor model ranks ICU Medical, Inc. 95 out of 100 as at 11 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ICUI stock forecast for 2030?

No analyst covering ICU Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICUI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $178 to $210 over the next 12 months.

How has ICUI stock performed over the past year?

ICU Medical, Inc. returned +24.5% over the 12 months to 11 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ICU Medical, Inc. do?

ICU Medical, Inc. is a medical technology company focused on infusion therapy, vascular access, and vital care products.

What is the latest news on ICUI?

The most recent item we track (GlobeNewsWire, 6 Nov 2026): "ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London". ICU Medical announced that company management will present at the 2026 Jefferies Global Healthcare Conference in London, scheduled for November 15–18, 2026.

Company

About ICU Medical, Inc.

ICU Medical, Inc. is a medical technology company focused on infusion therapy, vascular access, and vital care products. ICU Medical develops, manufactures, and sells a broad portfolio that includes IV pumps, needlefree connectors, IV administration sets, sterile IV solutions, closed-system transfer devices for hazardous drugs, and safety software used in hospital and alternate care settings. The company also offers hemodynamic monitoring, respiratory, anesthesia, temperature management, and other critical care products that support clinical workflows and patient safety. Its product families are designed to help healthcare providers deliver medications and fluids, reduce contamination risks, and improve efficiency across the IV continuum of care. ICU Medical serves acute care hospitals, ambulatory clinics, and home or alternate-site care environments, making it an important supplier in medical devices and hospital infrastructure.

CEO Mr. Vivek Jain · 13,000 employees · United States · https://www.icumed.com